Ed Silverman’s Pharmalittle column highlights comments attributed to Novo Nordisk chief executive Mike Doustdar, as reported by Reuters. Doustdar said investors may be underestimating the market demand for differentiation among obesity therapies. He suggested that the emergence of new treatment formats, including oral pills, will prevent the market from becoming a winner-take-all contest between Novo Nordisk and Eli Lilly.
The source reports that Novo was the first to introduce a highly effective GLP-1 weight-loss injection in the U.S., Wegovy, and that the company has faced pressure as Eli Lilly’s Zepbound has gained market share. Analysts cited in the Reuters coverage expect the obesity treatment market could be worth more than $100 billion per year by 2030, a projection the Pharmalittle item references to provide context for the strategic comments from Novo’s CEO.
Pharmalittle cites Reuters reporting that some drugmakers are withholding or delaying submissions for coverage under Switzerland’s mandatory health insurance system. The reason given is concern that lower prices secured through Swiss reimbursement decisions could affect the companies’ U.S. business under drug-pricing policies implemented by the U.S. administration referenced in the article.
The column points to a survey by Interpharma which indicates that about one-third of new innovative medicines were not submitted for reimbursement in Switzerland between January 2025 and June 2026. Pharmalittle notes that this behavior could limit patient access to new treatments in Switzerland, though the publicly available excerpt does not include additional granular details about which companies or products are affected or the survey methodology.
The Stat page includes a linked headline in the Most Popular list referencing California’s efforts to promote affordable insulin and an apparent slow start for a generic label (CalRx). That linked story appears adjacent to the Pharmalittle column in the source’s navigation, and the Pharmalittle piece references related coverage in its aggregation of industry news.
The public excerpt of the Pharmalittle column itself does not provide substantive details about California’s insulin program, the status of generic insulin distribution, or specific data on patient access. Because the article is marked a STAT+ exclusive and the detailed portion is behind the subscription wall, the specific reporting on California insulin availability was not included in the source text provided here.
The original Pharmalittle headline referenced a Moderna patent battle among other topics. However, the public portion of the source does not include narrative text or factual details about that patent dispute. The column aggregates several items and refers readers to reporting from outlets such as Reuters and to STAT+ premium content for deeper coverage.
Given that the STAT+ exclusive content is not included in the provided source text, specific facts, timelines, parties involved, or legal outcomes related to the Moderna patent matter were not reported and cannot be restated here.
This Pharmalittle item is identified as a STAT+ exclusive. The publicly available excerpt on the page summarizes or links to a few external reports (for example, Reuters coverage of Novo Nordisk and Interpharma’s survey), but the article’s full content and in-depth analysis are accessible only to STAT+ subscribers. Where the source text omits substantive details (for example, on the California insulin rollout and the Moderna patent dispute), those specifics are not reported in the excerpt and therefore are not included in this summary.
Readers seeking the complete reporting, including any additional examples, quotes, data, or analysis that the columnist provided, would need to consult the full STAT+ article or the original reporting cited (e.g., Reuters and the Interpharma survey) for further detail.